|
|
|
|
PA |
Controls |
|
|
|
|
|
Chamorro et al. 2005
22
|
136
|
67/69
|
NIHSS:
14 (7-19)/11 (7-18)
|
Levofloxacin 500 mg IV daily
|
Placebo
|
3 days
|
3 days
|
a, b, c, d
|
a, b, c, d
|
90
|
Lampl et al.
2007 19
|
151
|
74/77
|
NIHSS:
7.5 ± 3.2/7.6 ± 3.8
|
Minocycline 200mg orally daily
|
NPA
|
NPA
|
5 days
|
a, e, f
|
9
|
9
|
Harms et al.
2008 12
|
79
|
39/40
|
NIHSS:
17 (12-21)/
15 (12-15)
|
Moxifloxacin 400 mg IV daily
|
Placebo
|
5 days
|
5 days
|
a, b, c, d, e
|
180
|
180
|
Schwarz et al. 2008 16
|
60
|
30/30
|
NIHSS:
16.5 (8-28)/
15 (5-27)
|
Mezlocillin 2 g plus
sulbactam 1 g IV every 8 hours
|
NPA
|
4 days
|
4 days
|
a, b, c, d, e, h
|
90
|
90
|
Wang et al. 2012 17
|
165
|
83/82
|
GCS:
8.99 ± 3.92/
8.91 ± 4.16
|
Cefuroxime 3 g IV every 12 hours plus metronidazole 0.5 g IV every 12
hours, moxifloxacin 0.4 g IV daily for allergy to cephalosporins
|
NPA
|
NR
|
NR
|
a, c
|
NR
|
NR
|
Kohler et al.
2013 20
|
92
|
44/48
|
NIHSS:
9.1 ± 7.2/8.7±6.5
|
Minocycline 100 mg IV every 12 hours
|
NPA
|
5 doses
|
5 doses
|
a, b, c, d, e
|
90
|
90
|
Blacker et al. 2013 23
|
44 |
21/23 |
NR |
Minocycline
200 mg IV every 12 hours |
NPA |
5 doses |
5 doses |
a, e |
90 |
90 |
Kalra et al.
2015 11
|
1217
|
615/602
|
NIHSS:
15 (9–20)/
14 (9–20)
|
Local protocol
|
NPA
|
7 days
|
7 days
|
a, b, c, d, e, g, h
|
90
|
90
|
Ulm et al.
2016 18
|
227
|
112/115
|
NIHSS:
14 (12-18)/
15 (12-19)
|
The type and duration of
antibiotic treatment were left to the discretion of the treating
physician
|
NPA
|
Local
policy
|
Local
policy
|
a, b, c, d, e
|
90
|
90
|
Westendorp et al. 2015 10
|
2538
|
1268/
1270
|
NIHSS:
5 (3-9)/5 (3-9)
|
Ceftriaxone 2 g IV daily
|
NPA
|
4 days
|
4 days
|
a, b, c, d, e, g, h
|
90
|
90
|
Fouda et al.
2017 21
|
16
|
8/8
|
NR
|
Minocycline 400 mg IV once followed by 400 mg oral
|
Placebo
|
5 days
|
5 days
|
a, e, f
|
90
|
90
|
Mirtalaei et al. 2019
9
|
84
|
42/42
|
GCS:
6 ± 1.3/6.2 ± 1.5
|
Piperacillin-tazobactam 4 g/0.5 g IV
|
NPA
|
NR
|
NR
|
a, g
|
NR
|
NR
|